11,303 Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Acquired by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. bought a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQSTFree Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 11,303 shares of the company’s stock, valued at approximately $33,000.

Several other hedge funds and other institutional investors have also bought and sold shares of AQST. Dynamic Technology Lab Private Ltd bought a new stake in Aquestive Therapeutics during the 4th quarter valued at $44,000. Two Sigma Advisers LP bought a new stake in Aquestive Therapeutics during the 4th quarter valued at $57,000. PKS Advisory Services LLC bought a new stake in Aquestive Therapeutics during the 4th quarter valued at $63,000. Penbrook Management LLC bought a new stake in Aquestive Therapeutics during the 1st quarter valued at $65,000. Finally, Trust Point Inc. boosted its position in Aquestive Therapeutics by 69.9% during the 1st quarter. Trust Point Inc. now owns 23,396 shares of the company’s stock valued at $68,000 after acquiring an additional 9,625 shares in the last quarter. Institutional investors own 32.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on AQST shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Oppenheimer started coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They set an “outperform” rating and a $7.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Aquestive Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $10.14.

Read Our Latest Research Report on AQST

Aquestive Therapeutics Trading Down 0.2%

Shares of AQST opened at $4.02 on Wednesday. Aquestive Therapeutics, Inc. has a 12 month low of $2.12 and a 12 month high of $5.80. The stock has a fifty day moving average price of $3.15 and a 200-day moving average price of $3.02. The firm has a market cap of $399.31 million, a PE ratio of -6.81 and a beta of 1.97.

Aquestive Therapeutics (NASDAQ:AQSTGet Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $12.23 million. As a group, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

About Aquestive Therapeutics

(Free Report)

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Further Reading

Institutional Ownership by Quarter for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.